ARQT Arcutis Biotherapeutics, Inc. Stock Quote

ARQT [NASD]

Index	-	P/E	-	EPS (ttm)	-3.90	Insider Own	4.10%	Shs Outstand	43.03M	Perf Week	3.38%
Market Cap	1.44B	Forward P/E	-	EPS next Y	-5.04	Insider Trans	-4.32%	Shs Float	27.19M	Perf Month	-14.90%
Income	-135.70M	PEG	-	EPS next Q	-0.86	Inst Own	82.20%	Short Float	6.84%	Perf Quarter	-3.40%
Sales	-	P/S	-	EPS this Y	-231.80%	Inst Trans	17.48%	Short Ratio	6.94	Perf Half Y	13.81%
Book/sh	6.29	P/B	4.38	EPS next Y	-15.90%	ROA	-55.20%	Target Price	-	Perf Year	3.42%
Cash/sh	5.45	P/C	5.05	EPS next 5Y	9.80%	ROE	-60.70%	52W Range	17.51 - 39.85	Perf YTD	-2.17%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-30.95%	Beta	-
Dividend %	-	Quick Ratio	13.00	Sales past 5Y	-	Gross Margin	-	52W Low	57.17%	ATR	1.77
Employees	54	Current Ratio	13.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	42.88	Volatility	5.21% 6.61%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-130.60%	Profit Margin	-	Rel Volume	0.55	Prev Close	28.68
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	267.75K	Price	27.52
Recom	1.80	SMA20	-3.25%	SMA50	-13.37%	SMA200	0.22%	Volume	147,660	Change	-4.04%

Nov-09-20

Upgrade

Goldman

Neutral → Buy

$34 → $36

Oct-08-20

Initiated

Truist

Buy

$38

Feb-25-20

Initiated

Guggenheim

Buy

$36

Feb-25-20

Initiated

Goldman

Neutral

$30

Feb-25-20

Initiated

Cowen

Outperform

$55

Feb-25-20

Initiated

Cantor Fitzgerald

Overweight

$50

Apr-12-21 09:05AM	Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five Years GlobeNewswire
Mar-26-21 09:00AM	Arcutis Announces Updates to its Executive Team GlobeNewswire
Mar-18-21 09:05AM	Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo GlobeNewswire -6.34%
Mar-17-21 04:05PM	Arcutis Biotherapeutics to Showcase Long-term Safety, Efficacy, and Patient-Reported Outcomes of Roflumilast Cream for Chronic Plaque Psoriasis at Innovations in Dermatology: Virtual Spring Conference 2021 GlobeNewswire
Feb-25-21 05:15PM	Arcutis to Present at the Cowen 41st Annual Health Care Conference GlobeNewswire
Feb-18-21 09:00AM	Courtney Barton Joins Arcutis as Chief Compliance Officer and Chief of Staff GlobeNewswire
Feb-16-21 04:05PM	Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update GlobeNewswire
09:00AM	Arcutis Biotherapeutics Announces Closing of Underwriters Over-Allotment Option in Connection with Public Offering of Common Stock GlobeNewswire
Feb-06-21 01:14AM	How Many Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Do Institutions Own? Simply Wall St.
Feb-03-21 12:00PM	Arcutis Biotherapeutics, Inc. (ARQT) Upgraded to Buy: Here's Why Zacks
Feb-02-21 08:03PM	Arcutis Biotherapeutics Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire
Feb-01-21 04:09PM	Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire +30.38%
07:30AM	Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis GlobeNewswire
Jan-20-21 09:00AM	Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis GlobeNewswire
Jan-13-21 09:00AM	Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis GlobeNewswire
Jan-11-21 09:00AM	Matthew Moore Joins Arcutis as Chief Business Officer GlobeNewswire
Dec-21-20 09:27AM	Arcutis Biotherapeutics Added to Nasdaq Biotechnology Index GlobeNewswire
Dec-10-20 11:05PM	Is ARQT A Good Stock To Buy Now? Insider Monkey
Dec-09-20 09:00AM	Arcutis Highlights Advanced Pipeline & Unique Immuno-Dermatology Drug Development Capabilities at Virtual Investor Day on December 9, 2020 GlobeNewswire +6.74%
Dec-07-20 09:00AM	Arcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis GlobeNewswire
Dec-02-20 04:05PM	Arcutis to Host Virtual Investor Day on Wednesday, December 9, 2020 GlobeNewswire
Dec-01-20 04:05PM	Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis GlobeNewswire -8.41%
Nov-27-20 11:55AM	Goldman Sachs: These 3 Stocks Could Spike Over 40% TipRanks
Nov-23-20 07:30AM	Arcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp and Body Psoriasis GlobeNewswire +8.91%
Nov-11-20 04:05PM	Arcutis Biotherapeutics to Present at the Stifel 2020 Virtual Healthcare Conference GlobeNewswire
Nov-05-20 04:05PM	Arcutis Announces Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Nov-04-20 04:05PM	Arcutis Announces Appointment of Terrie Curran to Board of Directors GlobeNewswire
Nov-02-20 09:00AM	Arcutis Biotherapeutics Presents New Positive Data from Phase 2 Studies of ARQ-151 (Topical Roflumilast Cream) in Chronic Plaque Psoriasis and Atopic Dermatitis GlobeNewswire +5.05%
Oct-29-20 09:07PM	Arcutis Biotherapeutics to Present New Data from ARQ-151 (Topical Roflumilast Cream) Clinical Program at Three Global Dermatology Conferences GlobeNewswire
Oct-26-20 09:00AM	Arcutis Completes Enrollment in Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema GlobeNewswire -9.20%
Oct-08-20 10:00AM	Benzinga's Top Upgrades, Downgrades For October 8, 2020 Benzinga
Oct-06-20 04:05PM	Arcutis Biotherapeutics Announces Closing of Public Offering and Concurrent Private Placement of Common Stock GlobeNewswire
Oct-02-20 12:40PM	Why Arcutis Biotherapeutics Stock Is Plunging Today Motley Fool -15.64%
Oct-01-20 10:47PM	Arcutis Biotherapeutics Announces Pricing of Public Offering and Concurrent Private Placement of Common Stock GlobeNewswire -5.73%
Sep-29-20 04:51PM	Arcutis Biotherapeutics Announces Proposed Public Offering and Concurrent Private Placement of Common Stock GlobeNewswire +15.99%
02:36PM	Beyond Meat, Sohu.com: 5 Top Stock Gainers for Tuesday TheStreet.com
08:00AM	Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis GlobeNewswire
Sep-16-20 09:00AM	Arcutis Completes Enrollment in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis GlobeNewswire
Sep-15-20 09:00AM	Arcutis to Present at the Cantor Fitzgerald Global Healthcare Conference 2020 GlobeNewswire
Sep-08-20 09:00AM	Arcutis Biotherapeutics to Accelerate ARQ-151 (Topical Roflumilast Cream) into Phase 3 Trials for the Treatment of Atopic Dermatitis Following End-of-Phase 2 Meeting with FDA GlobeNewswire
Aug-11-20 04:02PM	Arcutis Announces Second Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Aug-10-20 09:00AM	Arcutis to Present at the Wedbush PacGrow Healthcare Conference GlobeNewswire +6.11%
Aug-04-20 09:00AM	Bethany Dudek Joins Arcutis as Vice President of Quality GlobeNewswire
Aug-03-20 09:00AM	The Journal of Drugs in Dermatology Publishes Results from Positive Phase 1/2a Trial of Arcutis ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis GlobeNewswire
Jul-31-20 09:00AM	Preliminary Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis GlobeNewswire
Jul-27-20 09:00AM	Arcutis Appoints Patrick Burnett, M.D., Ph.D., FAAD, as Chief Medical Officer GlobeNewswire
Jul-20-20 09:00AM	Arcutis Enrolls Last Patient in Phase 2b Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp Psoriasis GlobeNewswire
Jul-15-20 05:07PM	The New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis GlobeNewswire
Jul-13-20 09:00AM	Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema GlobeNewswire -5.23%
Jun-22-20 11:47AM	Is Arcutis Biotherapeutics, Inc. (ARQT) Going to Burn These Hedge Funds? Insider Monkey +8.17%
09:00AM	Arcutis Enrolls Last Patient in Phase 2 Proof of Concept Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis GlobeNewswire
Jun-10-20 04:05PM	Arcutis to Present at the Goldman Sachs 41st Annual Global Health Care Conference GlobeNewswire
Jun-01-20 09:00AM	Ayisha Jeter Joins Arcutis as Vice President of Market Access GlobeNewswire
May-27-20 09:00AM	Jay Ramsinghani Joins Arcutis as Vice President of Commercial Strategy and Operations GlobeNewswire
May-12-20 04:05PM	Arcutis Announces First Quarter 2020 Financial Results and Provides Business Update GlobeNewswire -7.84%
Apr-27-20 08:30AM	Halley E. Gilbert Appointed to Arcutis Board of Directors GlobeNewswire
Apr-21-20 09:00AM	Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema GlobeNewswire
Mar-23-20 08:30AM	Kimberly Lathroum Joins Arcutis as Vice President of Marketing GlobeNewswire +10.74%
Mar-16-20 08:37AM	Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis GlobeNewswire -16.24%
Mar-05-20 08:30AM	Heather Rowe Armstrong Joins Arcutis as Vice President of Investor Relations and Corporate Communications GlobeNewswire
Mar-03-20 08:30AM	Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for Late-Breaking Oral Presentation at the American Academy of Dermatology (AAD) Annual Meeting GlobeNewswire
Feb-19-20 08:30AM	Arcutis to Present at the Cowen 40th Annual Health Care Conference GlobeNewswire
Feb-14-20 08:00PM	Activist Investors Make Moves in Fiesta Restaurant, Chipotle Stock Barrons.com
Feb-13-20 08:30AM	Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis GlobeNewswire
Feb-04-20 04:05PM	Arcutis Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Watanabe Todd Franklin	President and CEO	Apr 05	Sale	29.93	1,750	52,378	595,416	Apr 06 05:30 PM
Welgus Howard G.	Director	Apr 01	Option Exercise	3.95	2,200	8,679	210,486	Apr 05 05:33 PM
Welgus Howard G.	Director	Apr 01	Sale	29.49	2,200	64,880	208,286	Apr 05 05:33 PM
CHAUDHURI BHASKAR	Director	Mar 22	Sale	31.10	10,000	311,021	871,391	Mar 24 11:33 AM
Welgus Howard G.	Director	Mar 16	Option Exercise	1.17	2,653	3,114	208,286	Mar 18 01:59 PM
Smither John W	Chief Financial Officer	Mar 10	Option Exercise	1.68	500	840	46,821	Mar 11 03:59 PM
Smither John W	Chief Financial Officer	Mar 10	Sale	32.90	1,250	41,125	86,715	Mar 11 03:59 PM
Smither John W	Chief Financial Officer	Mar 10	Sale	32.90	500	16,450	46,321	Mar 11 03:59 PM
Watanabe Todd Franklin	President and CEO	Mar 05	Sale	30.55	1,750	53,462	597,166	Mar 05 03:56 PM
Smither John W	Chief Financial Officer	Mar 04	Option Exercise	1.68	12,396	20,833	46,321	Mar 05 03:55 PM
Watanabe Todd Franklin	President and CEO	Mar 02	Sale	35.19	2,107	74,136	566,216	Mar 03 04:51 PM
Welgus Howard G.	Director	Mar 01	Option Exercise	3.92	2,200	8,626	207,833	Mar 03 04:45 PM
OSBORNE DAVID W	Chief Technical Officer	Mar 01	Sale	34.57	780	26,968	237,253	Mar 03 04:50 PM
Turney Patricia A.	SVP, Operations	Mar 01	Sale	34.52	934	32,242	9,271	Mar 03 04:49 PM
Lock Kenneth A.	Chief Commercial Officer	Mar 01	Sale	34.20	933	31,908	22,167	Mar 03 04:47 PM
Smither John W	Chief Financial Officer	Mar 01	Sale	34.20	773	26,440	24,425	Mar 03 04:48 PM
Welgus Howard G.	Director	Mar 01	Sale	34.37	2,200	75,610	205,633	Mar 03 04:45 PM
CHAUDHURI BHASKAR	Director	Feb 22	Sale	35.52	10,000	355,191	881,391	Feb 24 03:33 PM
Welgus Howard G.	Director	Feb 16	Option Exercise	1.17	2,654	3,116	205,633	Feb 17 08:35 PM
Smither John W	Chief Financial Officer	Feb 10	Option Exercise	1.68	750	1,260	25,948	Feb 12 05:32 PM
Smither John W	Chief Financial Officer	Feb 10	Sale	35.64	2,000	71,280	87,965	Feb 12 05:32 PM
Smither John W	Chief Financial Officer	Feb 10	Sale	35.64	750	26,730	25,198	Feb 12 05:32 PM
Watanabe Todd Franklin	President and CEO	Feb 05	Option Exercise	1.68	10,000	16,806	578,323	Feb 08 04:00 PM
Watanabe Todd Franklin	President and CEO	Feb 05	Sale	34.29	10,000	342,916	568,323	Feb 08 04:00 PM
Welgus Howard G.	Director	Feb 04	Option Exercise	1.68	19,861	33,378	202,979	Feb 08 01:45 PM
Smither John W	Chief Financial Officer	Feb 01	Option Exercise	1.68	1,250	2,101	26,448	Feb 03 11:23 AM
Welgus Howard G.	Director	Feb 01	Option Exercise	1.68	2,200	3,697	185,318	Feb 03 11:24 AM
Welgus Howard G.	Director	Feb 01	Sale	34.35	2,200	75,572	183,118	Feb 03 11:24 AM
Smither John W	Chief Financial Officer	Feb 01	Sale	35.00	3,750	131,250	89,965	Feb 03 11:23 AM
Smither John W	Chief Financial Officer	Feb 01	Sale	35.00	1,250	43,750	25,198	Feb 03 11:23 AM
CHAUDHURI BHASKAR	Director	Feb 01	Sale	33.25	9,949	330,804	891,391	Feb 02 07:39 PM
CHAUDHURI BHASKAR	Director	Jan 29	Sale	27.50	51	1,402	901,340	Feb 02 07:39 PM
Smither John W	Chief Financial Officer	Jan 19	Option Exercise	1.68	500	840	25,698	Jan 21 04:41 PM
Smither John W	Chief Financial Officer	Jan 19	Sale	30.00	1,250	37,500	93,715	Jan 21 04:41 PM
Smither John W	Chief Financial Officer	Jan 19	Sale	30.00	500	15,000	25,198	Jan 21 04:41 PM
Welgus Howard G.	Director	Jan 12	Option Exercise	0.58	1,222	709	183,118	Jan 14 11:11 AM
Welgus Howard G.	Director	Jan 04	Option Exercise	1.68	2,200	3,697	184,096	Jan 06 01:16 PM
Welgus Howard G.	Director	Jan 04	Sale	27.82	2,200	61,215	181,896	Jan 06 01:16 PM
Welgus Howard G.	Director	Dec 14	Option Exercise	0.58	1,222	709	181,896	Dec 16 03:14 PM
Smither John W	Chief Financial Officer	Dec 14	Option Exercise	1.68	1,500	2,521	26,698	Dec 16 03:14 PM
OSBORNE DAVID W	Chief Technical Officer	Dec 14	Sale	30.00	15,000	450,000	250,533	Dec 16 03:15 PM
Smither John W	Chief Financial Officer	Dec 14	Sale	30.00	3,750	112,500	94,965	Dec 16 03:14 PM
Smither John W	Chief Financial Officer	Dec 14	Sale	30.00	1,500	45,000	25,198	Dec 16 03:14 PM
Welgus Howard G.	Director	Dec 01	Option Exercise	1.68	2,200	3,696	182,044	Dec 03 07:40 PM
Welgus Howard G.	Director	Dec 01	Sale	25.98	2,200	57,155	179,844	Dec 03 07:40 PM
Welgus Howard G.	Director	Nov 12	Option Exercise	0.58	1,222	709	179,844	Nov 13 11:57 AM
Welgus Howard G.	Director	Nov 02	Option Exercise	1.68	2,200	3,696	180,822	Nov 04 04:33 PM
Welgus Howard G.	Director	Nov 02	Sale	18.27	2,200	40,186	178,622	Nov 04 04:33 PM
Lock Kenneth A.	Chief Commercial Officer	Oct 26	Option Exercise	6.52	2,668	17,395	21,863	Oct 27 02:03 PM
Lock Kenneth A.	Chief Commercial Officer	Oct 22	Option Exercise	6.52	2,695	17,571	19,195	Oct 23 01:27 PM
Lock Kenneth A.	Chief Commercial Officer	Oct 15	Option Exercise	6.52	7,500	48,900	16,500	Oct 16 02:06 PM
Welgus Howard G.	Director	Oct 15	Option Exercise	0.58	1,222	709	178,622	Oct 16 02:06 PM
ORBIMED ADVISORS LLC	Director	Oct 02	Buy	25.00	496,000	12,400,000	4,267,564	Oct 06 05:27 PM
SILVERSTEIN JONATHAN	Director	Oct 02	Buy	25.00	496,000	12,400,000	4,267,564	Oct 06 05:23 PM
Welgus Howard G.	Director	Oct 01	Option Exercise	1.68	2,200	3,696	179,210	Oct 05 09:13 PM
Welgus Howard G.	Director	Oct 01	Sale	27.65	2,200	60,829	177,400	Oct 05 09:13 PM
Watanabe Todd Franklin	President and CEO	Sep 29	Option Exercise	1.68	3,000	5,042	569,928	Oct 01 09:02 PM
Watanabe Todd Franklin	President and CEO	Sep 29	Option Exercise	1.68	3,000	5,042	569,928	Jan 07 02:39 PM
Smither John W	Chief Financial Officer	Sep 29	Option Exercise	1.68	500	840	24,375	Oct 01 09:00 PM
OSBORNE DAVID W	Chief Technical Officer	Sep 29	Sale	30.00	15,000	450,000	264,279	Oct 01 09:01 PM
Watanabe Todd Franklin	President and CEO	Sep 29	Sale	30.00	3,000	90,000	566,928	Jan 07 02:39 PM
Watanabe Todd Franklin	President and CEO	Sep 29	Sale	30.00	3,000	90,000	566,928	Oct 01 09:02 PM
Smither John W	Chief Financial Officer	Sep 29	Sale	30.00	1,250	37,500	98,715	Oct 01 09:00 PM
Smither John W	Chief Financial Officer	Sep 29	Sale	30.00	500	15,000	23,875	Oct 01 09:00 PM
Welgus Howard G.	Director	Sep 15	Option Exercise	0.58	1,222	709	177,400	Sep 16 05:57 PM
Welgus Howard G.	Director	Sep 01	Option Exercise	1.68	2,200	3,696	178,378	Sep 02 11:48 AM
Welgus Howard G.	Director	Sep 01	Sale	24.38	2,200	53,643	176,178	Sep 02 11:48 AM
Welgus Howard G.	Director	Aug 20	Option Exercise	1.68	5,000	8,400	176,178	Aug 21 02:19 PM
Welgus Howard G.	Director	Aug 18	Option Exercise	1.68	5,076	8,528	171,178	Aug 19 05:48 PM
Welgus Howard G.	Director	Aug 14	Option Exercise	0.58	6,110	3,545	166,102	Aug 18 04:12 PM
Welgus Howard G.	Director	Aug 03	Option Exercise	1.68	2,800	4,704	162,725	Aug 05 05:11 PM
Welgus Howard G.	Director	Aug 03	Sale	25.63	2,800	71,764	159,992	Aug 05 05:11 PM
Smither John W	Chief Financial Officer	Jun 11	Option Exercise	1.68	14,875	24,999	123,840	Jun 15 03:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience